

Express Mail Label No.: 95074974640US
Date of Deposit: July 17, 2003

3 0360
Attorney Docket No. 15966-557A (Cura 57A)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Jeffers, et al.
SERIAL NUMBER : 09/992,840 EXAMINER : Not Yet Assigned
FILING DATE : November 6, 2001 ART UNIT : Not Yet Assigned
FOR : Treatment of Inflammatory Bowel Disease Using Growth Factors

MAIL STOP IDS

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450



PATENT TRADEMARK OFFICE

TRANSMITTAL LETTER


Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Cited References B5-B7 and C49-C52;
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 15966-557A (Cura-57A). A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

 42,764

Ivor R. Elahi, Reg. No. 39,529

Attorney for Applicants

MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

Address all written correspondence to


Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: July 17, 2003

TRA 1814311v1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Jeffers, et al.
SERIAL NUMBER : 09/992,840 EXAMINER : Not Yet Assigned
FILING DATE : November 6, 2001 ART UNIT : Not Yet Assigned
FOR : Treatment of Inflammatory Bowel Disease Using Growth Factors

MAIL STOP IDS

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed within three months of the mailing dates of the Invitation to Pay Additional Fees for PCT/US 02/19400 and the International Search Report for PCT/US 01/43846 corresponding to the above-identified application. Reference C1 was enclosed in the Invitation to Pay Additional Fees. Accordingly, no fee or certification is believed due at this time.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by


APPLICANTS: Jeffers, et al.
U.S.S.N.: 09/992,840

35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.


Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 15966-557A (Cura-57A).

Respectfully submitted,


Ivor R. Elfi, Reg. No. 39,529
Attorney for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Address all written correspondence to
Customer no.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: July 17, 2003

TRA 1814315v1



Express Mail No.: EV074974640US

Date of Deposit: July 17, 2003

Page 1 of 1

Please type a plus sign (+) in this box



Modified Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	09/992,840
Filing Date	November 6, 2001
First Named Inventor	Jeffers, et al.
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	15966-557A

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B5	WO 01/07595	Curagen Corporation	02/01/01	
	B6	WO 01/68854	Amgen, Inc.	09/20/01	
	B7	WO 02/02625	Curagen Corporation	01/10/02	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C49	Bikfalvi, et al. (1997). Endocrine Reviews 18: 26-45.
	C50	Invitation to Pay Additional Fees for PCT/US 02/19400, mailed April 18, 2003.
	C51	Kirikoshi, et al. (2000). Biochem and Biophys Res Comm 274: 337-343.
	C52	International Search Report for PCT/US 01/43846, mailed May 9, 2003.

* A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.